Skip to main content

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.

Leest PV, Boonstra PA, Elst AT, Kempen LCV, Tibbesma M, Koopmans J, Miedema A, Tamminga M, Groen HJM, Reyners AKL, Schuuring E

Publication: Cancers (Basel) (2020) • Vol 12PMID: 32414097View on PubMed

Purpose

This paper compared the cell-free DNA (cfDNA) yield, integrity, fragment size, and variant allele frequency (VAF) in EDTA plasma or citrated diagnostic leukapheresis plasma when different extraction methods were used.

Conclusion

The yield of cfDNA from plasma varied among the extraction kits with significantly higher yields obtained from EDTA plasma using the QIAamp Circulating Nucleic Acid (CNA) Kit than the Maxwell RSC ccfDNA Plasma Kit (RSC) or the Zymo Quick ccfDNA Serum & Plasma Kit (Zymo) and from citrated diagnostic leukapheresis plasma using the QIAamp MinElute ccfDNA Midi Kit (MinElute) rather than the CNA kit. Significantly more of the 137 bp and 420 bp fragments of β-actin were amplified per mL of EDTA plasma when extraction was with the CNA Kit than the RSC or Zymo kits, but the MinElute Kit yielded more 50-250 bp fragments and a nonsignificant trend toward more 137 bp, 420 bp, and 1950 bp fragments of β-actin from citrated diagnostic leukapheresis plasma than the CNA Kit. Although there was no significant difference in the copies of the 137 bp fragment per ng cfDNA among the traditional EDTA plasma extraction methods (CNA, Zymo, and RSC), but the high volume MinElute Kit yielded more copies of the 137 bp fragment per ng cfDNA than the CNA Kit from citrated diagnostic leukapheresis plasma. Further, the ratio of short to medium fragments using the bioanalyzer and 137 to 420 bp amplicons did not differ among traditional extraction methods (CNA, Zymo, and RSC), but there was a higher ratio of small to medium sized fragments when extraction from citrated diagnostic leukapheresis plasma was with the MinElute Kit rather than the CNA Kit.

More copies of mutant ctDNA per mL EDTA plasma or per ng of cfDNA were obtained in two patients’ specimens when extraction was with the CNA Kit but more copies cfDNA per mL plasma were found when extraction was with RSC in the other two patients’ specimens. However, a higher number of copies of mutant cfDNA per mL of citrated diagnostic leukapheresis plasma was found when extraction was with MinElute rather than the CNA Kit from specimens for all six patients.  In three of four EDTA plasma specimens, the VAF was higher when extracted using the RSC than the CNA kit but the VAF was higher using the MinElute Kit rather than the CNA Kit in all six citrated diagnostic leukapheresis plasma specimens.

Studies (2)

Purpose

This study compared the cfDNA yield, integrity, fragment size, and VAF in EDTA when three different extraction methods were used. Plasma was collected from seven patients with gastrointestinal stromal tumor (GIST) into EDTA tubes and 11 patients with non-small cell lung carcinoma (NCSLC) into Streck cell-free BCT tubes. Plasma was obtained from GIST specimens by centrifugation for 10 min at 820 x g followed by 10 min at 16,000 x g within 4 h of blood collection. Plasma was obtained from NSCLC blood in BCT tubes by centrifugation for 10 min at 1600 x g followed by 10 min at 16,000 x g within 24 h of blood collection. cfDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid (CNA) Kit, the Maxwell RSC ccfDNA Plasma Kit (RSC), and the Zymo Quick ccfDNA Serum & Plasma Kit according to the manufacturer’s recommendations. cfDNA was quantified using the Qubit dsDNA HS Assay Kit and integrity assessed using a fragment analyzer. Amplificability of cfDNA was assessed using multiplex ddPCR amplification of 137 bp, 420 bp, and 1950 bp fragments of β-actin. KRAS G12/G13, BRAF G466V, PDGFRA M844_D846del, TP53 H179R, TP53 R273H, and TP53 Y205C mutations were detected using mutation-specific ddPCR.

Summary of Findings

The yield of cfDNA from plasma varied among the extraction kits with significantly higher yields obtained using the CNA than RSC or Zymo kits (P<0.001 and P<0.01, respectively). Importantly, the highest amount of cfDNA was obtained in 18 of 21 specimens using the CNA Kit and the lowest amount of cfDNA was obtained in 14 of 21 specimens using the RSC Kit. Significantly more of the 137 and 420 bp fragments of β-actin were amplified per mL of plasma when extraction was with the CNA than RSC (P<0.05 and P<0.01, respectively) or Zymo (P<0.0001 and P<0.001, respectively) kits and significantly higher amplification of the 1950 bp fragment was observed when extraction was with the CNA Kit than the RSC Kit (P<0.001). However, there was no significant difference in the copies of the 137 bp fragment when normalized to amount of cfDNA input. Further, the ratio of short to medium fragments using the bioanalyzer and 137 to 420 bp amplicons did not differ among extraction methods, but the ratio of 137 to 1950 bp fragments was significantly higher when extraction was with the RSC than the Zymo Kit (P<0.05), indicating a higher percentage of gDNA when extraction was with the Zymo Kit. 

More copies of mutant ctDNA per mL plasma or per ng cfDNA were obtained when extraction was with the CNA Kit in two patients’ specimens but more copies ctDNA per mL plasma were found when extraction was with RSC for the other two patients’ specimens. However, the VAF was higher when extracted using RSC than the CNA Kit in three of four specimens.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    Streck/BCTNone (Fresh)
  • Diagnoses

    NeoplasticCarcinoma
    NeoplasticSarcoma
  • Platforms

    DNAAutomated electrophoresis/Bioanalyzer
    DNAFluorometry
    DNADigital PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Analyte Extraction and PurificationAnalyte isolation method
    Maxwell RSC ccfDNA Plasma Kit (RSC)
    QIAamp Circulating Nucleic Acid (CNA) Kit
    Zymo Quick ccfDNA Serum & Plasma Kit